scholarly journals Individual and combined effects of GSTM1 and GSTT1 polymorphisms on colorectal cancer risk: an updated meta-analysis

2020 ◽  
Vol 40 (8) ◽  
Author(s):  
Liang Song ◽  
Chen Yang ◽  
Xiao-Feng He
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Tumor Location ◽  
Combined Effects ◽  
Gstm1 Null Genotype ◽  
Glutathione S Transferase ◽  
Gstt1 Null Genotype ◽  
T1 Gene ◽  
Meta Analyses

Abstract Background. The presence or absence of glutathione S-transferase M1 gene (GSTM1) and glutathione S-transferase T1 gene (GSTT1) polymorphisms, and their combined effects have been suggested as a risk factor for colorectal cancer (CRC). However, the results are inconsistent. Objectives. An updated meta-analysis was performed to solve the controversy. Methods. Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines were used. Results. Overall, the GSTM1 null genotype was associated with an increased CRC risk in Caucasians (odds ratio (OR) = 1.14, 95% confidence interval (CI): 1.05–1.23), Asians (OR = 1.19, 95% CI: 1.08–1.32), high-quality studies (OR = 1.12, 95% CI: 1.06–1.18). Moreover, the GSTM1 null genotype was also associated with an increased colon cancer risk (OR = 1.32, 95% CI: 1.16–1.51). The GSTT1 null genotype was also associated with an increased CRC risk in Asians (OR = 1.08, 95% CI: 1.02–1.15) and Caucasians (OR = 1.24, 95% CI: 1.09–1.41). Moreover, The GSTT1 null genotype was associated with an increased rectal cancer risk (OR = 1.13, 95% CI: 1.01–1.27, I2 = 8.3%) in subgroup analysis by tumor location. Last, the GSTM1 null/GSTT1 null genotype was associated with an increased CRC risk in Asians. Conclusion. This meta-analysis indicates that the GSTM1 and GSTT1 null genotypes are associated with increased CRC risk in Asians and Caucasians, and the GSTM1 null/GSTT1 null genotype was associated with increased CRC risk in Asians.

scholarly journals Association between the combined effects of GSTM1 present/null and CYP1A1 MspI polymorphisms with lung cancer risk: an updated meta-analysis

2020 ◽  
Vol 40 (9) ◽  
Author(s):  
Wen-Ping Zhang ◽  
Xiao-Feng He ◽  
Xiang-Hua Ye
Keyword(s):  
Lung Cancer ◽  
Meta Analysis ◽  
Combined Effects ◽  
Glutathione S Transferase ◽  
Increased Risk ◽  
Cyp1a1 Mspi ◽  
Discovery Probability ◽  
Positive Report ◽  
Meta Analyses ◽  
Positive Results

Abstract Background: Many studies have been performed to explore the combined effects of glutathione-S-transferase M1 (GSTM1) present/null and cytochrome P4501A1 (CYP1A1) MspI polymorphisms with lung cancer (LC) risk, but the results are contradictory. Two previous meta-analyses have been reported on the issue in 2011 and 2014. However, several new articles since then have been published. In addition, their meta-analyses did not valuate the credibility of significantly positive results. Objectives: We performed an updated meta-analysis to solve the controversy following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methods: False-positive report probability (FPRP), Bayesian false discovery probability (BFDP), and the Venice criteria were used to verify the credibility of meta-analyses. Results: Twenty-three publications including 5734 LC cases and 7066 controls met the inclusion criteria in the present study. A significantly increased risk of LC was found in overall analysis, Asians and Indians. However, all positive results were considered as ‘less-credible’ when we used the Venice criteria, FPRP, and BFDP test to assess the credibility of the positive results. Conclusion: These positive findings should be interpreted with caution and results indicate that significant associations may be less-credible, there are no significantly increased LC risk between the combined effects of GSTM1 present/null and CYP1A1 MspI polymorphisms.

Glutathione S-transferase P1 Ile105Val polymorphism and colorectal cancer risk: A meta-analysis and HuGE review

2009 ◽  
Vol 45 (18) ◽  
pp. 3303-3314 ◽  
Author(s):  
Yong Gao ◽  
Xiaofen Pan ◽  
Ting Su ◽  
Zengnan Mo ◽  
Yunfei Cao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Colorectal Cancer Risk ◽  
Glutathione S Transferase

scholarly journals Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis

2019 ◽  
Vol 17 (7) ◽  
pp. 805-811 ◽  
Author(s):  
Zi-Xian Wang ◽  
Hao-Xiang Wu ◽  
Ming-Ming He ◽  
Ying-Nan Wang ◽  
Hui-Yan Luo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Meta Analysis ◽  
Objective Response ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Tumor Location ◽  
Phase Iii ◽  
Left And Right ◽  
Meta Analyses

AbstractBackground: Previous meta-analyses have suggested primary tumor location as a predictive factor for efficacy of anti–epidermal growth factor receptor (EGFR) therapies in patients with metastatic colorectal cancer (mCRC). However, the recent phase III TAILOR trial addressing this issue was not included in those analyses. This meta-analysis incorporated data from the TAILOR trial to evaluate the efficacy of chemotherapy plus anti-EGFR agents (cetuximab [Cet] or panitumumab [Pani]) versus chemotherapy alone for RAS wild-type (wt) right- and left-sided mCRC. Patients and Methods: A PubMed-based literature search was conducted to identify randomized controlled trials (RCTs) studying the additional efficacy of Cet/Pani in combination with chemotherapy versus chemotherapy alone in RAS wt left- and right-sided mCRC. Study-level pooled analyses of hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) and odds ratios (ORs) for objective response rate (ORR) were performed. Results: Three first-line RCTs (CRYSTAL, PRIME, and TAILOR) and one second-line RCT (20050181) were included. Significant OS benefits from Cet/Pani were observed in the left-sided (HR, 0.76; 95% CI, 0.66–0.86) but not right-sided subgroups (HR, 0.99; 95% CI, 0.78–1.27). However, the addition of Cet/Pani to chemotherapy significantly improved PFS and ORR in both the left-sided (HR, 0.70; 95% CI, 0.57–0.86, and OR, 3.28; 95% CI, 1.95–5.51, respectively) and right-sided subgroups (HR, 0.76; 95% CI, 0.59–0.99, and OR, 1.78; 95% CI, 1.08–2.93, respectively). Conclusions: The addition of Cet/Pani to chemotherapy significantly benefits PFS and ORR in patients with RAS wt right-sided mCRC, indicating that anti-EGFR therapies may remain an option for selected patients.

Meta-analysis of cancer risk among users of insulin glargine.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1510-1510
Author(s):  
Alice Koechlin ◽  
Mathieu Boniol ◽  
Chris Robertson ◽  
Geremia Bolli ◽  
Julio Rosenstock ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Colorectal Cancer ◽  
Cancer Risk ◽  
Insulin Glargine ◽  
Meta Analysis ◽  
Short Exposure ◽  
Current Evidence ◽  
Meta Analyses ◽  
Risk Of Cancer

1510 Background: The association between diabetes, its risk factors and treatments, and cancer risk and death is now high on the clinical and research agenda. Methods: All data regarding cancer risk and use of insulin glargine has been assembled and meta-analyses performed using state-of-the-art statistical methodology. Glargine is the most studied insulin in this regard. A random effects model was employed with tests for heterogeneity (I2) and publication bias. These meta-analyses are based on reports from epidemiological studies involving a total of 907,008 diabetic subjects and 2,597,602 person-years of observation. Results: Based on independent estimates from 14 studies, the Summary Relative Risk (SRR) for all forms of cancer was (SRR=0.90, 95% CI (0.82, 0.98)) and for breast cancer SRR=1.14 (95% CI (1.00, 1.29)). For new users of glargine, from 7 studies, the SRR for breast cancer was SRR=1.20 (95% CI (0.90, 1.58)). Based on independent estimates for 9 studies, for colorectal cancer the SRR was 0.73 (95% CI (0.59, 0.91)) and for prostate cancer SRR=1.16 (95% CI (1.03, 1.30)). Overall, the risk of developing cancer among users of insulin glargine is reduced compared to the risk of users of other insulins. Similarly, the risk of colorectal cancer is reduced among users of glargine. While above unity, the risks of breast cancer and prostate cancer are increased marginally. Potential limitations to this meta-analysis include that the comparison group was not the same in all studies but this could also be seen as a strength. This is not likely to invalidate the findings of this analysis nor would the fact that different adjustments were made in the individual studies. Conclusions: The current evidence gives no support to the hypothesis that insulin glargine is associated with an increased risk of cancer as compared to other insulins and should give reassurance to physicians and their patients. Given the short exposure time possible to glargine (less than 5 years maximum), it is not biologically plausible to have a causal link to common forms of cancer.

Glutathione S-transferase T1 gene polymorphism and colorectal cancer risk: An updated analysis

2013 ◽  
Vol 37 (6) ◽  
pp. 626-635 ◽  
Author(s):  
Xian-peng Qin ◽  
Yong Zhou ◽  
Yi Chen ◽  
Ning-ning Li ◽  
Bo Chen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Risk ◽  
Gene Polymorphism ◽  
Colorectal Cancer Risk ◽  
Glutathione S Transferase ◽  
T1 Gene
Sign in / Sign up

Export Citation Format

Share Document